• Alfasigma acquires the European license for bentracimab from PhaseBio prnasia
    June 22, 2021
    Alfasigma has entered into an exclusive licensing agreement with PhaseBio Pharmaceuticals, Inc., for the commercialization of bentracimab in 49 countries across Europe and other key markets.
  • PhaseBio and BioVectra Enter into Supply Agreement contractpharma
    March 12, 2021
    ​PhaseBio Pharmaceuticals, a clinical-stage biotech focused on the development and commercialization of novel therapies for cardiopulmonary diseases, and BioVectra, a global contract development and manufacturing organization (CDMO), have entered a ...
PharmaSources Customer Service